All In Biotech

Drug Trial Radar · NCT06912763

Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)

Last checked: Nov 20, 2026Latest source record: Jul 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 250 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

250

Planned (sponsor's estimate)

Start

Aug 8, 2025

Primary completion

Jul 31, 2030

Study completion Jul 31, 2031

Sponsor

Lead sponsor
M.D. Anderson Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Single group
Masking
Double (participant, outcomes assessor)
Primary purpose
Supportive care
FDA-regulated drug
Yes
Who can join
Female only
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To find out if adding medication can help treat or prevent lymphedema and/or fibrosis related to radiation therapy, in survivors of head and neck cancer. Researchers will compare these drugs to find the most effective therapy for preventing or limiting these side effects.

Conditions

  • Fibrosis Syndrome
  • Lymphedema
  • Head &Amp; Neck Cancer
  • Fibrosis

Interventions

  • Pravastatin (drug)Drug

    Given PO

  • PentoxifyllineDrug

    Given PO

  • ketoprofenDrug

    Given PO

  • PirfenidoneoneDrug

    Given PO

  • Standard of Care (SOC)Other

    SOC

  • tocopherolDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and adverse eventsTime frame: Through study completion; an average of 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.